02:13:57 Europe / Stockholm

Prenumeration

2024-06-17 07:52:00

Redeye initiates coverage of Coegin Pharma, a hub and spoke biotech company with a diverse array of potential revenue streams. Through its three established portfolio companies, Coegin Pharma develops a robust pipeline of first-in-class pharmaceutical and cosmetic products. With a spread-out operational risk and platform-driven optionality, we see an attractive risk-reward profile with ample potential to create increased shareholder value ahead.

Read more and download the Research Report.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/